Skip to main content

ADHD

The US Food and Drug Administration has approved Supernus Pharmaceuticals’ Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in patients aged 6 to 17 years.
The digital therapeutic treatment AKL-T01 significantly improved attention-deficit/hyperactivity disorder (ADHD) symptoms and related impairments in both children who used, and did not use, stimulant medication.
Less green space surrounding a child’s home may be associated with a higher risk of developing attention-deficit/hyperactivity disorder (ADHD), according to a study published online in Environmental Health Perspectives.
Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) may have an increased risk of a subsequent psychotic disorder (PD), according to a meta-analysis recently published online in JAMA Psychiatry.
Task-based functional connectivity can serve as a biomarker for attention-deficit/hyperactivity disorder (ADHD), according to a study published online in Frontiers in Physiology.
Back to Top